COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 1000: Articles 9991-10000  | Next

Modelling Quarantine Effects on SARS-CoV-2 Epidemiological Dynamics in Chilean Communes and their Relationship with the Social Priority Index
Salinas, D. G., Bustamante, M. L., Gallardo, M. O.
10.1101/2022.01.21.22269658 — Posted: 2022-01-23
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the Delta variant epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
Maeda, H., Saito, N., Igarashi, A., Ishida, M., Suami, K., Yagiuchi, A., Kimura, Y., Komino, M., Arai, H., Morikawa, T., Motohashi, I., Miyazawa, R., Moriyama, T., Kamura, H., Terada, M., Kuwamitsu, O., Hayakawa, T., Sando, E., Ohara, Y., Teshigawara, O., Suzuki, M., Morimoto, K.
10.1101/2022.01.17.22269394 — Posted: 2022-01-23
Does a humoral correlate of protection exist for SARS-CoV-2? A systematic review
Perry, J. A., Osman, S., Wright, J., Richard-Greenblatt, M., Buchan, S. A., Sadarangani, M., Bolotin, S.
10.1101/2022.01.21.22269667 — Posted: 2022-01-23
Predictive performance and clinical application of COV50, a urinary proteomic biomarker in early COVID-19 infection: a cohort study
Staessen, J. A., Wendt, R., Yu, Y.-L., Thijs, L., Siwy, J., Raad, J., Metzger, J., Neuhaus, B., Papkalla, A., von der Leyen, H., Mebazaa, A., Dudoignon, E., Spasovski, G., Milenkova, M., Canevska-Taneska, A., Psichogiou, M., Rajzer, M. W., Fulawka, L., Dzitkowska-Zabielska, M., Weiss, G., Feldt, T., Stegemann, M., Normark, J., Zoufaly, A., Schmiedel, S., Seilmaier, M., Rumpf, B., Banasik, M., Krajewska, M., Catanese, L., Rupprecht, H., Czerwienska, B., Peters, B., Nilsson, A., Rothfuss, K., Luebbert, C., Mischak, H., Beige, J.
10.1101/2022.01.20.22269599 — Posted: 2022-01-23
Proteomic deconvolution reveals distinct immune cell fractions in different body sites in SARS-Cov-2 positive individuals
Okendo, J., Okanda, D.
10.1101/2022.01.21.22269631 — Posted: 2022-01-23
The Effects of Messaging on Expectations and Understanding of Long COVID: An Online Randomised Trial
Bhogal, J. K., Mills, F., Dennis, A., Spoiala, C., Milward, J., Saeed, S., Jones, L. F., Weston, D., Carter, H.
10.1101/2022.01.18.22269467 — Posted: 2022-01-23
Impact of COVID-19 symptoms on social aspects of life of female long haulers: A qualitative study
Aghaei, A., Zhang, R., Taylor, S., Tam, C. C., Yang, C.-H., Li, X., Qiao, S.
10.1101/2022.01.21.22269671 — Posted: 2022-01-23
Waning of Vaccine-Conferred Protection against SARS-CoV-2 Infection: Matched Case-Control Test-Negative Design Study in Two High-Risk Populations
Goldhaber-Fiebert, J. D., Prince, L., Chin, E. T., Leidner, D., Studdert, D. M., Salomon, J. A., Andrews, J. R.
10.1101/2022.01.21.22269664 — Posted: 2022-01-23
Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2)
PERALTA SANTOS, A., Pinto Leite, P., Casaca, P., Fernandes, E., Freire Rodrigues, E., Moreno, J., Ricoca, V., Gomes, J. P., Ferreira, R., Isidro, J., Pinto, M., Borges, V., Vieira, L., Duarte, S., Sousa, C., Menezes, L., Almeida, J. P., Ferreira, B., Matias, A., Pelorito, A., Freire, S., Grilo, T., Medeiro Borges, C., Moutinho, V., Kislaya, I., Rodrigues, A. P., Leite, A., Nunes, B.
10.1101/2022.01.20.22269406 — Posted: 2022-01-23 Discussion: Offsite
B.1.617.2 SARS-CoV-2 (Delta) variant is associated with increased risk of hospitalization and death compared with B.1.1.7 SARS-CoV-2 (Alpha) variant
Freire Rodrigues, E., Moreno, J., Pinto Leite, P., Nunes, B., Gomes, J. P., Ferreira, R., Isidro, J., Borges, V., Vieira, L., Duarte, S., Sousa, C., Almeida, J. P., Menezes, L., Vaz, D., Leite, A., PERALTA SANTOS, A.
10.1101/2022.01.21.22268602 — Posted: 2022-01-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).